Positron emission tomography using a newly-developed PET probe: [18F] Fluoroacetate (FACE) - human volunteer study
Phase 1
- Conditions
- healthy volunteer
- Registration Number
- JPRN-UMIN000007575
- Lead Sponsor
- Shiga Medical Center Research Institute
- Brief Summary
Annals of Nuclear Medicine Ann Nucl Med (2014) 28:371-380 Assessment of [18F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 4
Inclusion Criteria
Not provided
Exclusion Criteria
a person with a disease (diseases)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dynamic data acquisition (0 min after the intravenous injection up to 3hr after injection) using PET machine.
- Secondary Outcome Measures
Name Time Method Radiation exposure will be also evaluated using dynamic data.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of [18F]fluoroacetate (FACE) in tumor imaging for liver cancer via TCA cycle inhibition?
How does [18F]fluoroacetate (FACE) PET/CT compare to [18F]FDG PET/CT in detecting liver tumors in clinical trials?
Which metabolic biomarkers correlate with [18F]fluoroacetate (FACE) uptake in liver tumor imaging studies?
What adverse events were observed in Phase I trials of [18F]fluoroacetate (FACE) in healthy volunteers and how were they managed?
Are there alternative PET tracers for liver tumor imaging, and how does [18F]fluoroacetate (FACE) differ in targeting metabolic pathways?